Clinical experience with daptomycin in Europe: The first 2.5 years

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 912-919

  Gonzalez Ruiz, Armando ^a   Beiras Fernandez, Andres ^b   Lehmkuhl, Hans ^c   Seaton, R Andrew ^d   Loeffler, Juergen ^e   Chaves, Ricardo L ^e  

^a DARENT VALLEY HOSPITAL   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cyclic lipopeptide; Gram positive infections; Registry

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEPHALOSPORIN; DAPTOMYCIN; GLYCOPEPTIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AUSTRIA; BACTEREMIA; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENDOCARDITIS; ENTEROCOCCUS FAECIUM; EUROPE; FEMALE; FRANCE; GERMANY; GREECE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; RETROSPECTIVE STUDY; SKIN INFECTION; SLOVENIA; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DAPTOMYCIN; ENTEROCOCCUS FAECIUM; EUROPE; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952776386     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq528     Document Type: Article

References (29)

1. Novartis Europharm Ltd. Cubicin (daptomycin) Summary of Product Characteristics. 2009.
2. Cubist pharmaceuticals. Cubist investor relations. http://www.cubist.com/investor_relations (23 November 2009, date last accessed).
3. Rolston KV, Segreti J, Lamp KC et al. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 2007; 120 Suppl 1: S4-5.
4. Mohr JF, Friedrich LV, Yankelev S et al. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009; 33: 543-8.
5. Chamberlain RS, Culshaw DL, Donovan BJ et al. Daptomycin for the treatment of surgical site infections. Surgery 2009; 146: 316-24.
6. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
7. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
8. Falagas ME, Vouloumanou EK, Sgouros K et al. Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents. Int J Antimicrob Agents 2010; 36: 1-13.
9. Gonzalez-Ruiz A, Lamp KC, Lin MY et al. Safety and effectiveness of daptomycin in patients with renal insufficiency not requiring renal replacement therapy. In: Abstracts of the Twentieth European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 2010. Abstract 1235, p. S345. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
10. Owens RC Jr, Lamp KC, Friedrich LV et al. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 2007; 120 Suppl 1: S6-12.
11. Sakoulas G, Golan Y, Lamp KC et al. Daptomycin in the treatment of bacteremia. Am J Med 2007; 120 Suppl 1: S21-7.
12. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007; 120 Suppl 1: S28-33.
13. Lamp KC, Friedrich LV, Mendez-Vigo L et al. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007; 120 Suppl 1: S13-20.
14. Lamp K, Friedrich L. Clinical experience trends with daptomycin in the first two years: report from a registry. In: Abstracts of the Seventeenth European Congress of Clinical Microbiology and Infectious Diseases, Munich, 2007. Abstract 838, p. S213. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
15. Gudiol F, Aguado JM, Pascual A et al. [Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistant Staphylococcus aureus. Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica]. Enferm Infecc Microbiol Clin 2009; 27: 105-15.
16. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
17. Gonzalez-Ruiz A, Richardson J. Are glycopeptides still appropriate and convenient for empiric use? J Chemother 2008; 20: 531-41.
18. Alder J, Eisenstein B. The advantage of bactericidal drugs in the treatment of infection. Curr Infect Dis Rep 2004; 6: 251-3.
19. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-72.
20. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
21. Rolston KV, McConnell SA, Brown J et al. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol 2010; 8: 249-56, 90.
22. Canton R, Ruiz-Garbajosa P, Chaves RL et al. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010; 65: 1126-36.
23. Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin Microbiol Infect 2009; 15 Suppl 6: 11-6.
24. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs 2006; 66: 1089-105.
25. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2009; 30: 2369-413.
26. Oleson FB Jr, Berman CL, Kirkpatrick JB et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44: 2948-53.
27. Cosgrove SE, Vigliani GA, Fowler VG Jr et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48: 713-21.
28. Thibault N, Grenier L, Simard M et al. Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob Agents Chemother 1994; 38: 1027-35.
29. Pharmacia Ltd. Zyvox (linezolid) Summary of Product Characteristics. 2007.